{"entity":{"id":"andrew-armstrong","kind":"person","name":"Andrew J. Armstrong","aka":[],"tldr":"Led ARCHES, which established enzalutamide with hormone therapy for metastatic hormone-sensitive prostate cancer.","summary":"Andrew Armstrong was principal investigator of ARCHES, the trial showing enzalutamide plus androgen deprivation improves radiographic progression-free and overall survival in metastatic hormone-sensitive prostate cancer, and led the PROPHECY study validating AR-V7 in circulating tumour cells as a marker of resistance to AR inhibitors. He directs prostate cancer research at Duke.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Armstrong%20AJ%5BAuthor%5D%20enzalutamide%20ARCHES"}],"tags":["prostate","trialist"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["androgen-deprivation","liquid-biopsy"],"targets":["androgen-receptor"],"drugs":[],"companies":[],"institutions":["duke-cancer-institute"],"pathways":[],"terms":[],"trials":["arches"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Surgery, and Pharmacology and Cancer Biology, Duke Cancer Institute","institutionId":"duke-cancer-institute","specialisms":["Prostate cancer","Androgen receptor inhibitors","Biomarkers of resistance","Circulating tumour cells"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Armstrong%20AJ%5BAuthor%5D%20enzalutamide%20ARCHES"}],"papers":[{"title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","journal":"JCO","year":2019,"doi":"10.1200/JCO.19.00799"},{"title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study","journal":"JCO","year":2019,"doi":"10.1200/JCO.18.01731"}],"orcid":"0000-0001-7012-1754"},"route":"/people/andrew-armstrong/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"androgen-deprivation","kind":"technology","name":"Androgen deprivation & AR pathway inhibitors","route":"/technologies/androgen-deprivation/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"target":[{"id":"androgen-receptor","kind":"target","name":"Androgen receptor","route":"/targets/androgen-receptor/"}],"institution":[{"id":"duke-cancer-institute","kind":"institution","name":"Duke Cancer Institute","route":"/institutions/duke-cancer-institute/"}],"trial":[{"id":"arches","kind":"trial","name":"ARCHES","route":"/trials/arches/"}]}}